Aessen Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 04-10-2024
- Paid Up Capital ₹ 7.41 M
as on 04-10-2024
- Company Age 65 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -68.86%
(FY 2023)
- Profit -72.81%
(FY 2023)
- Ebitda 406.83%
(FY 2023)
- Net Worth 10.94%
(FY 2023)
- Total Assets 6.91%
(FY 2023)
About Aessen
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.41 M, as per Ministry of Corporate Affairs (MCA) records.
Surendra Jangir, Prabhudas Gohil, and Kalpana Umakanth serve as directors at the Company.
- CIN/LLPIN
U29219PB1959PTC052647
- Company No.
089300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 1959
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Aessen?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendra Jangir  | Director | 29-May-1999 | Current |
| Prabhudas Gohil | Director | 01-Jun-2021 | Current |
| Kalpana Umakanth | Director | 11-Nov-2011 | Current |
Financial Performance of Aessen.
Aessen Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 68.86% decrease. The company also saw a substantial fall in profitability, with a 72.81% decrease in profit. The company's net worth Soared by an impressive increase of 10.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aessen?
In 2023, Aessen had a public holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Walter Bushnell Medicines Private LimitedActive 17 years 5 monthsSurendra Jangir is a mutual person
Walter Bushnell Lifescience Private LimitedActive 2 years 9 monthsPrabhudas Gohil and Kalpana Umakanth are mutual person
Walter Bushnell Pharmaceuticals Private LimitedActive 20 years 14 daysSurendra Jangir is a mutual person
Walter Bushnell Healthsciences Private LimitedActive 17 years 5 monthsPrabhudas Gohil is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aessen?
Unlock and access historical data on people associated with Aessen, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aessen, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aessen's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
